pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
363
stories
10h
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
15h
Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds
endpoints
15h
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
1d
STAT+: Experts scrutinize Huidagene’s disclosures after patient death
stat
1d
Amylin design debate heats up as Lilly's crucial mid-stage weight loss data near
endpoints
1d
Enveda’s exercise-simulating obesity tablet clears early clinical test
biospace
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
2d
STAT+: Real-world psilocybin data suggest need for close monitoring
stat
2d
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
biospace
2d
STAT+: Amylyx endocrine drug succeeds in pivotal study
stat
2d
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
stat
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
6d
Opinion: U.S., U.K. health care systems share a fatal flaw
stat
7d
STAT+: Eli Lilly targets booming black market for retatrutide
stat
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
7d
STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
stat
7d
Opinion: How to disrupt the health misinformation business model
stat
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
8d
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide
biopharma dive
8d
Lilly cracks down on black market for obesity asset retatrutide with six lawsuits
biospace
8d
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
stat
8d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
8d
After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
fiercebiotech
9d
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
stat
9d
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
stat
13d
STAT+: NIH plans to block international researchers on visas from accessing key funding avenue
stat
13d
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
13d
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
fiercebiotech
14d
STAT+: FDA approves Replimune melanoma drug previously rejected twice
stat
← prev
page 1 of 13
next →
